RxDoctor Payments Data

John Costa, MD

Cardiovascular Disease · Las Vegas, NVNPI 1043219041

Payments from drug & device makers

$673in general payments, 2019–2025

Across 31 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$166
  • Pfizer$164
  • Novartis$76
  • E.r. Squibb & Sons, L.L.C.$43
  • GE HealthCare$41
  • Johnson & Johnson$25
  • plus $159 from 10 others

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$673 in reported general payments places this provider in the 20th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$62,138
Medicare patients
290
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$173,502
EntrestoSacubitril/Valsartan45$57,591
XareltoRivaroxaban29$24,978
Atorvastatin Calcium223$1,864
Nifedipine ErNifedipine72$1,653
Metoprolol Succinate152$1,649
Carvedilol111$1,287
Rosuvastatin Calcium76$667
Ezetimibe45$645
Amiodarone Hcl39$459
Amlodipine Besylate67$455
Metoprolol Tartrate53$378
Lisinopril68$358
Losartan Potassium58$355
Hydralazine Hcl15$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$164$173,502125 claims
NovartisEntresto$76$57,59145 claims
Johnson & JohnsonXarelto$25$24,97829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →